Plenary Keynotes

Tuesday, August 6, 2019 | 4:15 - 5:30 pm

PANEL DISCUSSION: Next-Generation Immunotherapies

CHI’s Immuno-Oncology Summit brings you the latest advances in immunotherapy every year. This panel of industry thought leaders will discuss the technology advances and implementation strategies for next-generation immunotherapies, including emerging immunotherapy combinations, bispecific antibodies, oncolytic virotherapy, adoptive cell therapy, personalized vaccines and neoantigen targeted therapies, small molecules and ADCs, cytokines, and innate immunity targeted therapies.

Moderator

Pamela Carroll, PhD

Senior Vice President, Immuno-Oncology, Genocea Biosciences

 

 

 

 

Panelists

Rakesh Dixit

PhD, DABT, President & CEO, Bionavigen

 

 

 

 

Tara Arvedson, PhD

Director, Oncology Research, Amgen

 

 

 

 

Stephen Doberstein, PhD

Senior Vice President, R&D and Chief Research and Development Officer, Nektar Therapeutics

 

 

 

 

Raymond Tesi, MD

CEO/CMO, INmune Bio

 

 

 

 

David Kirn, MD

Co-Founder & Executive Chairman, IGNITE Immunotherapy

 

 

 

 

Thursday, August 8, 2019 | 8:25 - 9:30 am

PANEL DISCUSSION: Partnering and Licensing in Immuno-Oncology

Big pharma and biotech are under pressure to compete in the booming Immuno-Oncology market and to capitalize on new technologies and innovations to bring next-generation immunotherapies to the patients. This insider panel will share what they look for in a partner or investment, and discuss opportunities for collaboration or in-licensing of novel immunotherapies, IO targets or biomarkers, and potential combination therapies.

Moderator

Jeroen H. Blokhuis, PhD

Director, Business Development, Partnerships, Parker Institute for Cancer Immunotherapy

 

 

 

 

Panelists

Michael Woo, MBA

Head, Search & Evaluation, Immuno-Oncology, Business Development & Licensing, Novartis Institutes for BioMedical Research, Inc.

 

 

 

 

Kathryn McCabe, PhD

Senior Director, Business Development, Emerging Technology and Innovation, Eli Lilly and Company

 

 

 

 

Scott M. DeWire, PhD

Global Head, Business Development and Licensing, Cancer Immunology, Boehringer Ingelheim Pharmaceuticals, Inc.

 

 

 

 

Philip Arlen, MD

President & CEO, Precision Biologics

 

 

 

 

Stephen Doberstein, PhD

Senior Vice President, R&D and Chief Research and Development Officer, Nektar Therapeutics

Japan-Flag Korea-Flag China-Traditional-Flag China-Simplified-Flag


Connect With Us

MEETING SUGGESTIONS

For meeting questions or suggestions, please contact:

Julia Boguslavsky
Executive Director, Conferences
Cambridge Healthtech Institute
juliab@healthtech.com

PARTNERING & SPONSORSHIP

For partnering and sponsorship info, please contact:

Rod Eymael
Manager, Business Development
Cambridge Healthtech Institute
+1 781.247.6286
reymael@healthtech.com

MEDIA & ASSOCIATION

For media and association partnerships, please contact:

Pete DeOlympio
Sr. Marketing Manager
Cambridge Healthtech Institute
+1 781.972.5415
peted@healthtech.com